TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB42794

Peptide_Name

TAT-327

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

CancerPPD 2.0

Sequence_Type

standard

Has_Modification No

Description A 18-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.

Sequence

RKKRRQRRREFLDCFQKF

FASTA

>TPDB42794|Anticancer|length=18
RKKRRQRRREFLDCFQKF

Formula C109H181N41O25S1

Absent Amino Acids ANGHIMPSTWYV

Common Amino Acids R

Mass 2497.96

PI 12.12

Basic Residues 9

Acidic Residues 2

Hydrophobic Residues 4

Net Charge +7

Boman Index 8.05

Hydrophobicity -2.111

Aliphatic Index 21.67

Half Life

Mammalian: 1 hour Yeast: 2 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 3

number

0

A

6

R

0

N

1

D

1

C

1

E

2

Q

0

G

0

H

0

I

1

L

3

K

0

M

3

F

0

P

0

S

0

T

0

W

0

Y

0

V

Amino Acid Distribution

A: 0 R: 6 N: 0 D: 1 C: 1 E: 1 Q: 2 G: 0 H: 0 I: 0 L: 1 K: 3 M: 0 F: 3 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0

Length

18

Formula

C109H181N41O25S1

Mass

2497.96

PI

12.12

Net Charge

+7

Boman Index

8.05

Hydrophobicity

-2.111

C_terminal_Modification

Free

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Anticancer

Origin

Peptide-327

Evidence 1 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 = 55.42 ± 0.84 µM

Detail Source Activity Anticancer

Activity Measurement 55.42

Target

Cancer Type Lung Cancer

Cell Line A-549

Tissue Affected Lung

Assay & Model

Assay CCK-8 assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2018

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 = 68.52 ± 2.96 µM

Detail Source Activity Anticancer

Activity Measurement 68.52

Target

Cancer Type Liver Cancer

Cell Line HepG-2

Tissue Affected Liver

Assay & Model

Assay CCK-8 assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2018

Evidence 3 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 = 68.40 ± 0.42 µM

Detail Source Activity Anticancer

Activity Measurement 68.40

Target

Cancer Type Colon Cancer

Cell Line Colo-320

Tissue Affected Colon

Assay & Model

Assay CCK-8 assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2018

Evidence 4 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 = 74.08 ± 0.63 µM

Detail Source Activity Anticancer

Activity Measurement 74.08

Target

Cancer Type Colon Cancer

Cell Line HT-29

Tissue Affected Colon

Assay & Model

Assay CCK-8 assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2018

Evidence 5 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 = 64.61 ± 1.63 µM

Detail Source Activity Anticancer

Activity Measurement 64.61

Target

Cancer Type Colorectal Cancer

Cell Line SW-620

Tissue Affected Colon

Assay & Model

Assay CCK-8 assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2018